رجوع
نطاق اليوم
KWD 1.79
KWD 2.04
نطاق 52 أسبوعًا
KWD 0.57
KWD 2.73
حجم التداول
17,353,935
متوسط 50 يوم / 200 يوم
KWD 1.72
/
KWD 1.37
الإغلاق السابق
KWD 2.10
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -9.3 | 0.4 |
| P/B | — | 2.9 |
| ROE % | -776.9 | 3.7 |
| Net Margin % | -1537.4 | 3.9 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | — | 0.2 |
السعر المستهدف للمحللين
Hold
KWD 5.000
+160.4%
Low: KWD 3.500
High: KWD 6.000
ربحية السهم المستقبلية
-KWD 0.223
الإيرادات المقدّرة
1.7 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2030 |
KWD 1.605
KWD 0.505 – KWD 3.245
|
1 B | 2 |
| FY2029 |
KWD 0.648
KWD 0.204 – KWD 1.309
|
500 M | 2 |
| FY2028 |
KWD 0.015
-KWD 0.400 – KWD 0.830
|
170 M | 4 |
Insider Trading Activity
7 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 |
Ramachandran Ramesh
Chief Accounting Officer
|
grant | 518,250 | — | — |
| Jan 2, 2026 |
Musunuri Shankar
Chief Executive Officer
|
grant | 6,246,402 | — | — |
| Jun 5, 2025 |
Chandrasekhar Satishchandran
Director
|
grant | 151,316 | — | — |
| Jun 5, 2025 |
Castillo Kirsten
Director
|
grant | 151,316 | — | — |
| Jun 5, 2025 |
Kompella Uday
Director
|
grant | 151,316 | — | — |
| Jun 5, 2025 |
Coleman Blaise
Director
|
grant | 151,316 | — | — |
| Jun 5, 2025 |
Zhang Junge
Director
|
grant | 151,316 | — | — |
النقاط الرئيسية
Negative free cash flow of -57.15M
Capital efficient — spends only 4.19% of revenue on capex
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)8.83%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-776.89%
ROIC-224.94%
Net Margin-1537.41%
Op. Margin-1425.70%
الأمان
Debt / Equity
N/A
Current Ratio1.06
Interest Coverage-12.13
التقييم
P/E Ratio
-9.28
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.83% | Revenue Growth (3Y) | -14.49% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 4.41M | Net Income (TTM) | -67.85M |
| ROE | -776.89% | ROA | -155.91% |
| Gross Margin | 45.86% | Operating Margin | -1425.70% |
| Net Margin | -1537.41% | Free Cash Flow (TTM) | -57.15M |
| ROIC | -224.94% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1.06 |
| Interest Coverage | -12.13 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -9.28 | P/B Ratio | N/A |
| P/S Ratio | 142.66 | PEG Ratio | -0.40 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 629.56M | Enterprise Value | 644.14M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.41M | 4.06M | 6.04M | 2.49M | 0.0 |
| Net Income | -67.85M | -54.05M | -63.08M | -86.80M | -58.37M |
| EPS (Diluted) | -0.23 | -0.20 | -0.26 | -0.40 | -0.30 |
| Gross Profit | 2.02M | 2.09M | 5.33M | 2.49M | 0.0 |
| Operating Income | -62.92M | -54.76M | -65.53M | -89.07M | -58.03M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 43.52M | 82.44M | 64.55M | 108.63M | 105.76M |
| Total Liabilities | 56.46M | 52.81M | 23.98M | 34.65M | 9.94M |
| Shareholders' Equity | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M |
| Total Debt | 33.14M | 32.50M | 6.94M | 6.37M | 3.31M |
| Cash & Equivalents | 18.57M | 58.51M | 39.46M | 77.56M | 94.96M |
| Current Assets | 24.34M | 61.68M | 42.97M | 98.49M | 102.65M |
| Current Liabilities | 23.04M | 21.59M | 17.09M | 28.53M | 7.00M |